PAHC vs ZOMDF vs BFLY Stock Comparison

Phibro Animal Health, Zomedica and Butterfly Network Prices as of Nov 5, 2026 Peers: Industry group
1 more company in this comparison (MRK) Create a free account to keep reading and compare up to 10 companies.
ZOMDF Zomedica Corp.
$0.09 +12.5% 1M +12.5% 1Y
Market cap
$92.41M
P/E
–
Revenue (TTM)
$38.68M
Div. yield
–
Animal Health Healthcare
1 win
BFLY Butterfly Network, Inc.
$6.05 -30.5% 1M +141.0% 1Y
Market cap
$1.67B
P/E
–
Revenue (TTM)
$123.25M
Div. yield
–
Diagnostic Equipment Healthcare
3 wins

Head to Head

7 decided of 12

Butterfly Network leads on 3 of the 12 questions below (Butterfly Network 3, Phibro Animal Health 3, Zomedica 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionPAHCZOMDFBFLYLeader
Larger companyMarket capitalisation $1.34B $92.41M $1.67B BFLY
Cheaper on earningsLower P/E, profitable companies only 13.1x -5.8x -31.1x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 10.4x — — –
Faster revenue growthRevenue growth, trailing twelve months +10.1% +31.3% +39.4% BFLY
More profitableNet margin, trailing twelve months 6.7% -41.4% -43.6% PAHC
Better return on capitalReturn on invested capital 13.9% — — –
Less leveragedLower net debt / EBITDA 2.1x — — –
Higher dividend yieldTrailing dividend yield 0.01% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -14.0% +12.5% +141.0% BFLY
Better 5-year returnAnnualised price return, 5 years +9.6%/yr -29.9%/yr -10.3%/yr PAHC
Less volatileAnnualised volatility, 1 year 56.6% 104.0% 112.8% PAHC
Higher overall scoreMean of the five percentile scores vs peers 70/100 76/100 49/100 ZOMDF

Percentile Scorecard

PAHCZOMDFBFLY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisPAHCZOMDFBFLY
Valuation 94 #38 of 634 75 #161 of 634 29 #164 of 229
Growth 85 #90 of 608 80 #121 of 608 90 #24 of 221
Profitability 85 #86 of 557 74 #147 of 557 38 #131 of 210
Financial Health 27 #476 of 654 74 #174 of 654 57 #103 of 240
Shareholder Returns 57 #175 of 403 – 34 #97 of 147
Overall 70 76 49
  • PAHC ranked among 671 companies in Pharmaceuticals and Biotechnology
  • ZOMDF ranked among 671 companies in Pharmaceuticals and Biotechnology
  • BFLY ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodPAHCZOMDFBFLYSPY
1 month -3.3%+12.5%-30.5% -5.9%
3 months -0.3%0.0%-27.1% -4.6%
6 months -18.0%-10.0%+42.7% +0.2%
Year to date -5.2%-10.0%+59.2% +7.5%
1 year -14.0%+12.5%+141.0% +8.2%
3 years +189.5%-52.6%+476.2% +68.3%
3 years, per year +42.5%-22.1%+79.3% +19.0%
5 years +58.2%-83.0%-42.0% +56.5%
5 years, per year +9.6%-29.9%-10.3% +9.4%
10 years +35.1%—— +251.5%
10 years, per year +3.1%—— +13.4%

Risk

MeasurePAHCZOMDFBFLYSPY
Volatility, 1Y 56.6%104.0%112.8% 13.6%
Downside volatility, 1Y 61.6%161.8%94.6% 14.2%
Beta vs S&P 500, 1Y 0.940.133.00 1.00
Return / volatility, 1Y -0.250.121.25 0.60
Max drawdown, 5Y -57.9%-94.8%-93.1% -25.4%
From 52-week high -40.6%-40.0%-39.1% -5.9%
52-week high $59.58$0.15$9.94 $779.14
52-week low $28.52$0.07$1.97 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultiplePAHCZOMDFBFLY
P/E now vs peer median 14.0xmedian 17.8x -5.5xmedian 17.8x -29.5xmedian 26.9x
P/S now vs peer median 0.9xmedian 8.1x 2.3xmedian 8.1x 12.1xmedian 2.9x
EV/EBITDA now vs peer median 7.7xmedian 15.7x -4.8xmedian 15.7x -26.8xmedian 17.5x
P/FCF now vs peer median 66.3xmedian 21.0x -7.4xmedian 21.0x -54.0xmedian 26.4x
P/B now vs peer median 3.4xmedian 2.0x 0.8xmedian 2.0x 8.1xmedian 2.3x
PEG now vs peer median 0.20median 0.36 2.38median 0.36 -0.99median 0.88

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsPAHCZOMDFBFLY
Revenue $1.54B $38.68M $123.25M
Gross profit $521.27M $24.74M $86.60M
Operating income $192.78M -$17.57M -$57.83M
Net income $102.71M -$16.00M -$53.69M
Free cash flow $21.67M -$11.92M -$27.55M
R&D – $5.07M $39.57M
EPS (diluted) $2.51 $-0.02 $-0.20
Cash & equivalents $75.55M $7.28M $122.30M
Total debt $610.88M – –
Shares (diluted) 40.96M 979.95M 262.10M
Enterprise value $1.02B -$92.61M $1.13B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricPAHCZOMDFBFLY
P/E 14.0x -5.5x -29.5x
P/FCF 66.3x -7.4x -54.0x
P/Operating cash flow 16.8x -7.7x -63.6x
P/S 0.9x 2.3x 12.1x
P/B 3.4x 0.8x 8.1x
P/Tangible book 3.7x 1.3x 8.4x
EV/EBITDA 7.7x -4.8x -26.8x
EV/EBIT 10.2x -2.7x -23.6x
EV/Revenue 1.3x 1.2x 11.1x
EV/FCF 90.7x -4.0x -49.6x
EV/Operating cash flow 22.9x -4.2x -58.4x
PEG (3Y EPS CAGR) 0.20 2.38 -0.99

Growth

14 metrics
MetricPAHCZOMDFBFLY
Revenue growth (1Y) 10.1% 31.3% 39.4%
Revenue CAGR (3Y) 16.4% 17.2% 21.7%
Gross profit growth (1Y) 19.5% 23.3% 126.4%
Gross profit CAGR (3Y) 20.6% 14.6% 30.5%
Operating income growth (1Y) 33.8% 79.9% 33.5%
Operating income CAGR (3Y) 49.7% 11.5% 26.9%
Net income growth (1Y) 51.5% 81.1% 32.8%
Net income CAGR (3Y) 70.5% -2.3% 24.2%
EPS growth (1Y) 51.2% 81.1% 35.4%
EPS CAGR (3Y) 69.8% -2.3% 30.0%
Operating cash flow growth (1Y) 11.6% 46.1% 5.8%
Operating cash flow CAGR (3Y) 28.7% 4.9% 41.1%
Free cash flow growth (1Y) -36.8% 46.6% -0.1%
Free cash flow CAGR (3Y) 74.0% 20.1% 38.8%

Profitability

14 metrics
MetricPAHCZOMDFBFLY
Gross margin 33.8% 64.0% 70.3%
EBITDA margin 16.5% -26.1% -41.4%
Operating margin 12.5% -45.4% -46.9%
Pretax margin 9.1% -41.7% -43.5%
Net margin 6.7% -41.4% -43.6%
FCF margin 1.4% -30.8% -22.4%
Operating cash flow margin 5.6% -29.7% -19.0%
Return on equity 25.6% -15.1% -28.7%
Return on assets 6.8% -13.7% -18.8%
Return on invested capital 13.9% – –
Return on capital employed 15.9% -16.3% -26.6%
Asset turnover 1.0x 0.3x 0.4x
Cash conversion (OCF / net income) 0.8x 0.7x 0.4x
Stock comp / revenue 0.1% 3.6% 20.8%

Financial Health

11 metrics
MetricPAHCZOMDFBFLY
Debt / assets 40.3% – –
Debt / equity 1.5x – –
Net debt / EBITDA 2.1x – –
Debt / FCF 28.2x – –
Liabilities / assets 72.4% 9.3% 36.0%
Equity / assets 27.6% 90.7% 64.0%
Interest coverage 4.2x – -46.8x
Current ratio 3.2x 6.1x 3.6x
Quick ratio 1.0x 5.2x 2.3x
Cash ratio 0.3x 4.4x 1.8x
Altman Z-score 3.09 1.45 4.66

Shareholder Returns

7 metrics
MetricPAHCZOMDFBFLY
Dividend yield 1.4% – –
Net buyback yield – – -0.6%
Shareholder yield 1.4% – -0.6%
Payout ratio (earnings) 19.0% – –
Payout ratio (FCF) 89.9% – –
Dividend growth (1Y) 0.1% – –
Dividend CAGR (3Y) 0.0% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusPAHCZOMDFBFLY
Forward P/E 10.4xFY2027 – –
EPS, next fiscal year $3.42FY2027 $-0.03FY2026 $-0.06FY2026
EPS growth, next FY +6.2%FY2027 – –
EPS growth, the year after +9.6% – –
Revenue, next fiscal year $1.53BFY2027 $46.29MFY2026 $117.62MFY2026
Revenue growth, next FY +0.6%FY2027 +44.5%FY2026 +20.5%FY2026
Revenue growth, the year after -0.2% +31.6% +22.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersPAHCZOMDFBFLY
Held by institutions 99.1% 0.0% 58.4%
Institutions holding 210 6 248
Change in shares held, QoQ +3.0% -98.8% +13.9%
Institutions buying 117 2 144
Institutions selling 75 0 59
Buyers to sellers 1.56 – 2.44

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

PAHCZOMDFBFLY
PAHC 1.00 0.00 0.13
ZOMDF 0.00 1.00 0.10
BFLY 0.13 0.10 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, PAHC, ZOMDF and BFLY?

Butterfly Network (BFLY) is the largest by market capitalisation: Phibro Animal Health (PAHC) $1.34B, Zomedica (ZOMDF) $92.41M, Butterfly Network (BFLY) $1.67B.

Which company is growing faster?

Butterfly Network (BFLY) grew revenue fastest over the trailing twelve months: Phibro Animal Health (PAHC) +10.1%, Zomedica (ZOMDF) +31.3%, Butterfly Network (BFLY) +39.4%.

Which company is more profitable?

Phibro Animal Health (PAHC) has the highest net margin (Phibro Animal Health (PAHC) 6.7%, Zomedica (ZOMDF) -41.4%, Butterfly Network (BFLY) -43.6%).

Which stock has performed better?

Over the past year Butterfly Network (BFLY) returned the most: Phibro Animal Health (PAHC) -14.0%, Zomedica (ZOMDF) +12.5%, Butterfly Network (BFLY) +141.0%. Over five years, Phibro Animal Health (PAHC) compounded fastest (Phibro Animal Health (PAHC) +9.6%/yr, Zomedica (ZOMDF) -29.9%/yr, Butterfly Network (BFLY) -10.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Phibro Animal Health (PAHC) 0.01%, Zomedica (ZOMDF) 0.00%, Butterfly Network (BFLY) 0.00%. Zomedica (ZOMDF) and Butterfly Network (BFLY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Phibro Animal Health (PAHC) has been the steadiest (Phibro Animal Health (PAHC) 56.6%, Zomedica (ZOMDF) 104.0%, Butterfly Network (BFLY) 112.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, PAHC, ZOMDF and BFLY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Butterfly Network (BFLY) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.